Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
The effect of the interval-between-sessions on prefrontal transcranial direct current stimulation (tDCS) on cognitive outcomes: a systematic review and meta-analysis.
Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
Calpain inhibition attenuated morphological and molecular changes in skeletal muscle of experimental allergic encephalomyelitis rats.
No impact of adult attachment and temperament on clinical variability in patients with clinically isolated syndrome and early multiple sclerosis.
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Increased axonal expression of nectin-1 in multiple sclerosis plaques.
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.
Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
CHMP assessment report for Sovrima (International nonproprietary name: idebenone)
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review.
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
A comparative study of experimental mouse models of central nervous system demyelination.
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
The extent of ultrastructural spinal cord pathology reflects disease severity in experimental autoimmune encephalomyelitis.
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
Artielle Immunotherapeutics Announces Positive Results of Phase ! Multiple Sclerosis Trial
Effect of High-Dose Intravenous Methyl-prednisolone Treatment on Intraocular Pressure in Multiple Sclerosis Patients with Relapse.
Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients.
Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.

Pages